X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
The payment triggered under the agreement is following the European approval of Rezzayo (rezafungin acetate), a novel, once-weekly echinocandin antifungal approved for the treatment of invasive candidiasis in adults.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Rezzayo
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Mundipharma
Deal Size: $568.0 million Upfront Cash: $39.0 million
Deal Type: Partnership February 12, 2024
Details:
Rezzayo (rezafungin) is a novel once-weekly echinocandin, a 1,3-beta-glucan synthase inhibitor. It is approved for the treatment of invasive candidiasis.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Rezzayo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2024
Details:
Rezzayo (rezafungin acetate) is a novel once-weekly echinocandin antifungal approved by USFDA. It is now approved by MHRA for the treatment of invasive candidiasis in adults.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Rezzayo
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2024
Details:
Rezzayo (rezafungin) is an echinocandin antifungal that helps to inhibit the synthesis of 1,3-beta-D-glucan, an essential component of fungal cell walls. It recently got EU approval for the treatment of invasive candidiasis in adults.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Rezzayo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2023
Details:
Rezzayo (rezafungin) is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Rezzayo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2023
Details:
Rezzayo (rezafungin acetate) is a novel once-weekly echinocandin and 1,3-beta-glucan synthase inhibitor. It is approved for the treatment for Invasive Candidiasis in adults.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Rezzayo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2023
Details:
Rezafungin is a novel once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as invasive candidiasis and candidemia.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Rezzayo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cidara Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2023
Details:
Rezzayo (rezafungin) is a novel, once-weekly, next-generation echinocandin, an antifungal being used for the treatment and prevention of adult patients with candidemia and invasive candidiasis.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Rezzayo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Details:
Rezzayo (rezafungin) is a novel, once-weekly, next-generation echinocandin, an antifungal being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Rezzayo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2023
Details:
Under the agreement, Melinta acquired exclusive rights to commercialize Rezzayo (rezafungin) in the U.S. from Cidara. Cidara recently received FDA approval for REZZAYO™, a novel, once-weekly echinocandin antifungal approved for candidemia and invasive candidiasis.
Lead Product(s): Rezafungin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Rezzayo
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Melinta Therapeutics
Deal Size: $460.0 million Upfront Cash: $30.0 million
Deal Type: Licensing Agreement April 24, 2023
Details:
Rezzayo (rezafungin) is a novel, once-weekly, next-generation echinocandin, an antifungal being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Rezzayo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Melinta Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2023
Details:
CD101 (rezafungin) is a novel, once-weekly antifungal being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: CD101
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Cantor Fitzgerald & Co.
Deal Size: $19.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 07, 2023
Details:
CD101 (rezafungin) is a novel, once-weekly antifungal being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: CD101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cantor Fitzgerald & Co.
Deal Size: $17.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 03, 2023
Details:
CD101 (rezafungin) is a member of the echinocandin class of drugs. Echinocandins are considered the safest antifungal drugs available and are suggested by the Infectious Disease Society of America (IDSA) as first-line treatment for fungal infections.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: CD101
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Melinta Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2023
Details:
Rezafungin is a novel once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: CD101
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Melinta Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2022
Details:
CD101 (rezafungin) is a novel, once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections,demonstrated non-inferiority to the current standard of care in the treatment of candidemia and/or invasive candidiasis.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: CD101
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2022
Details:
Rezafungin is a novel once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: CD101
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Mundipharma
Deal Size: $568.0 million Upfront Cash: $30.0 million
Deal Type: Licensing Agreement October 04, 2022
Details:
Rezafungin (CD101) is a novel, once-weekly echinocandin antifungal being developed for the treatment of candidemia and invasive candidiasis, as well as for the prophylaxis of invasive fungal infections in patients undergoing allogeneic blood and marrow transplant.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: CD101
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022
Details:
European Medicines Agency filing is supported by the pivotal ReSTORE Phase III clinical trial results, where rezafungin (echinocandin/CD101) demonstrated non-inferiority to the current standard of care, caspofungin in the treatment of candidemia and/or invasive candidiasis.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: CD101
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
Under the terms of the Agreement, Cidara will continue to lead the ongoing global Phase 3 ReSPECT prophylaxis study, as well as the regulatory activities for the approval of CD101 (rezafungin) in both the treatment and prophylaxis indications.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: CD101
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Cidara Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 27, 2022
Details:
Results from ReSTORE showed primary endpoints were met with, 23.7% all-cause mortality on day 30 for rezafungin compared to 21.3% for caspofungin global cure on day 14 of 59.1% for rezafungin and 60.6% for caspofungin.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: CD101
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Cidara Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2022
Details:
Result, did not demonstrate highly potent antifungal properties of CD101 against Candida in preclinical animal models of VVC, CD101 IV has enhanced potency and is only once-weekly therapy intended for treatment and prevention of life-threatening invasive fungal infections.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: CD101
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Mundipharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2022
Details:
PIM designation, early indication that CD101, next-generation echinocandin may be eligible for Early Access to Medicines Scheme in UK permits use of medicines not yet approved by regulatory authorities for treatment of invasive candidiasis and candidemia.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: CD101
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Cidara Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2022
Details:
Rezafungin is a novel once-weekly echinocandin currently being studied in Phase 3 trials for the treatment and prevention of serious fungal infections in critically ill patients.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: CD101
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Mundipharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2021
Details:
Rezafungin is a novel once weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: CD101
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2021
Details:
Cidara will share new findings related to rezafungin, its novel once-weekly echinocandin in Phase 3 trials for the treatment and prevention of serious fungal infections, in three poster presentations.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: CD101
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 11, 2021
Details:
Rezafungin is a novel, once-weekly echinocandin, currently in Phase 3 clinical trials for both the treatment of invasive candidiasis and prophylaxis against severe invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: CD101
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Cidara Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2021
Details:
Posters presenting new analyses from completed Phase 2 STRIVE trial support the efficacy and pharmacokinetics of once-weekly rezafungin in the treatment of candidemia and invasive candidiasis.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2020
Details:
First patient dosed in ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead antifungal candidate, rezafungin, for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2020
Details:
Abstracts highlight new data on Company’s antifungal rezafungin program and preclinical data on its Cloudbreak antiviral program. Ph 2 trial shows superiority of rezafungin in time to clear infection.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2020
Details:
The presentations showcased Cidara’s rezafungin program for the treatment and prophylaxis of invasive fungal infections.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
